Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Exemestane seems to stimulate tumour growth in men with prostate carcinoma.

Bonomo M, Mingrone W, Brauchli P, Hering F, Goldhirsch A; Swiss Group for Clinical Cancer Cancer Research, a member of the Swiss Institute of Applied Cancer Research..

Eur J Cancer. 2003 Sep;39(14):2111-2. No abstract available.

PMID:
12957469
2.

Exemestane following tamoxifen in postmenopausal women with primary breast cancer.

Mouridsen HT.

J Clin Oncol. 2004 Sep 15;22(18):3833-4. No abstract available.

PMID:
15365083
3.

Drug helps slow advanced prostate cancer.

Printz C.

Cancer. 2012 Oct 1;118(19):4641. doi: 10.1002/cncr.27828. No abstract available.

4.

[Metastatic prostate cancer: new insights and developments].

Lorch A.

Dtsch Med Wochenschr. 2013 Apr;138(14):703-6. doi: 10.1055/s-0032-1332995. Epub 2013 Mar 26. Review. German. No abstract available.

PMID:
23533034
5.

Weekly chemotherapeutic regimen in metastatic prostate cancer.

Burk K.

Prog Clin Biol Res. 1990;350:187-200. Review.

PMID:
2201043
6.

TNP-470 combined with nicardipine suppresses in vivo growth of PC-3, a human prostate cancer cell line.

Arisawa C, Kageyama Y, Kawakami S, Kihara K.

Urol Oncol. 2002 Nov-Dec;7(6):229-34.

PMID:
12504843
7.

The endocrinology and treatment of prostate tumor progression.

Bruchovsky N, Brown EM, Coppin CM, Goldenberg SL, Le Riche JC, Murray NC, Rennie PS.

Prog Clin Biol Res. 1987;239:347-87. Review. No abstract available.

PMID:
3309961
8.

Exemestane: the dawn of a new era in breast cancer treatment.

Kapoor S.

J Cancer Res Clin Oncol. 2008 Jul;134(7):819-20. doi: 10.1007/s00432-008-0363-9. Epub 2008 Feb 12. No abstract available.

PMID:
18266008
9.

Steroidal side effects of exemestane.

Nabholtz JM.

J Clin Oncol. 2001 Apr 1;19(7):2107-8. No abstract available.

PMID:
11283149
10.

Bone loss with exemestane: Is the jury still out?

Cheung AM, Tomlinson G, Goss PE.

J Clin Oncol. 2005 Dec 20;23(36):9433-4; author reply 9433-5. No abstract available.

PMID:
16361646
11.

Cancer progression in the kidney and prostate: vital roles of sphingolipids in chemotherapy.

Radin NS.

Urology. 2002 Oct;60(4):562-8. Review. No abstract available.

PMID:
12385907
12.

[Study of anti-cancer chemotherapy of prostatic carcinoma. I. Comparative study of ifosfamide and VIP against a hormone-independent human prostatic carcinoma cell line].

Moriyama N, Usui T, Nagafuji T, Ohsumi Y, Ishibe T.

Gan To Kagaku Ryoho. 1987 Aug;14(8):2589-93. Japanese. No abstract available.

PMID:
3619466
13.

Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

Taneja SS.

J Urol. 2013 Sep;190(3):880. doi: 10.1016/j.juro.2013.05.104. Epub 2013 Jun 7. No abstract available.

PMID:
23931193
14.

[ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].

Perrone F.

Tumori. 2006 Jul-Aug;92(4):suppl 1-9. Review. Italian. No abstract available.

PMID:
17036536
15.

Abiraterone in metastatic prostate cancer.

Raymond LW, Carr JP, Only C.

N Engl J Med. 2013 Apr 11;368(15):1457-8. doi: 10.1056/NEJMc1301594#SA2. No abstract available.

PMID:
23574135
16.

Abiraterone in metastatic prostate cancer.

Kichenadasse G, Karapetis C.

N Engl J Med. 2013 Apr 11;368(15):1457. doi: 10.1056/NEJMc1301594#SA1. No abstract available.

PMID:
23574134
17.

Abiraterone in metastatic prostate cancer.

Ryan CJ, Molina A, Griffin T.

N Engl J Med. 2013 Apr 11;368(15):1458-9. doi: 10.1056/NEJMc1301594. No abstract available.

18.

[Chemotherapy of hormone refractory prostate carcinoma].

Wirth MP, Nippgen J.

Urologe A. 2003 Nov;42(11):1453-60. Review. German.

PMID:
14624343
19.

Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.

Naik H, Lehr JE, Pienta KJ.

Urology. 1996 Sep;48(3):508-11.

PMID:
8804514
20.

New treatment strategies in advanced prostate cancer.

Small EJ, Reese DM.

Radiol Clin North Am. 2000 Jan;38(1):203-11, ix-x. Review.

PMID:
10664673

Supplemental Content

Support Center